Bullish
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Refractory Triple Negative Breast Cancer
Cellectar Biosciences has enrolled the first patient in its Phase 1b clinical trial of CLR 125, an Auger-emitting radioconjugate, for refractory tripl...